Ireland's Cosmo recurring revenue rises on winlevi growth, reaffirms FY guidance

Cosmo NV

23/07/2026 06:16

    

    Overview
  
Ireland-based specialty pharma's H1 recurring revenue rose 18% yr/yr, driven by Winlevi and Lialda
Total H1 revenue dipped slightly yr/yr, company posted net loss for the period
Company ended H1 debt-free with over €205 mln in cash, reaffirmed full-year guidance

    

    Outlook
  
Cosmo reaffirms 2026 revenue guidance at €105–110 mln, recurring revenue €98–102 mln
Company expects 2026 EBITDA of €10.5–13.5 mln and year-end cash around €200 mln
Cosmo expects double-digit growth for GI Genius in H2 and full-year 2026

    

    Result Drivers
  
WINLEVI GROWTH - Winlevi recurring revenue rose 38% yr/yr, driven by increased manufacturing and supply activities, especially for European launches
LIALDA PERFORMANCE - Lialda recurring revenue rose 35% yr/yr, reflecting continued strength in the company's gastrointestinal franchise
CDMO EXPANSION - CDMO recurring revenue rose 14% yr/yr, supported by new customer wins and expanded manufacturing activities

    
Company press release: ID:nNFC30VJC6

    

    Key Details
  

            Metric
          

            Beat/Miss
          

            Actual
          

            Consensus Estimate
          
H1 Revenue
 
EUR 50.2 mln
 
H1 Loss Per Share
 
EUR 0.279
 

    

    Analyst Coverage
  
The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 5 "strong buy" or "buy", no "hold" and no "sell" or "strong sell"
The average consensus recommendation for the pharmaceuticals peer group is "buy"
Wall Street's median 12-month price target for Cosmo Pharmaceuticals NV is CHF123.00, about 92.5% above its July 22 closing price of CHF63.90
The stock recently traded at 100 times the next 12-month earnings vs. a P/E of 120 three months ago

    

    Reuters Recommended Reads
  
July 21 - Novartis backs full year forecast after $6 billion profit beat helped by one-offs
July 20 - Veterinary drugmaker Virbac's H1 revenue rises on Supercharge platform strength
July 22 - Pfizer's prostate cancer drug combination gets US FDA priority review

    
For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)